Meridian Bioscience (VIVO) Issues FY09, Reaffirms FY08 Outlook; Intends to Recommend Qtr. Dividend Increase
More News related to VIVO
- Meridian Bioscience Announces Filing of Shelf Registration Statement to Replace Expiring Registration Statement
- Meridian Bioscience to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
- Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Beats by 1c; Reaffirms FY09 Outlook
- Meridian Bioscience Reports Record Fiscal 2008 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
- New Molecular Test for C. difficile from Meridian Bioscience Expected to be Launched in Fiscal Year 2009
More News related to Dividends
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Meridian Bioscience, Inc (NASDAQ: VIVO) sees FY09 sales of $157-$160 million, versus the consensus of $159.66 million and EPS in the range of $0.86-$0.90, versus the Street estimate of $0.88. Meridian also reaffirmed its previously issued FY08 sales and EPS guidance of $140-$142 million and $0.72-$0.75, respectively. The Street is expecting sales of $139.88 million and EPS of $0.73 for FY08.
Meridian also said that management intends to recommend another increase to its quarterly dividend.
Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.
Related Categories
DividendsGuidance
Stocks Mentioned
+0.65Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
